Gemcitabine 1 g Powder for Solution for Infusion clinical trials
3 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Open-label, Randomized Study of Nivolumab Combined with Ipilimumab, or with Standard of Care Chemotherapy, versus Standard of Care Chemotherapy in Participants with Previously Untreated Unresectable or Metastatic Urothelial Cancer
This study is looking at new ways to treat bladder cancer that has spread or can't be removed with surgery. It compares a new combination of medicines with standard chemotherapy to see which works best at helping people live longer. Participants will be randomly assigned to different treatment groups.
For: Untreated Unresectable or Metastatic Urothelial CancerGermany · Greece · Denmark - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Randomized, Open-Label, Phase 3 Trial of Nivolumab plus Ipilimumab or Nivolumab plus Platinum-Doublet Chemotherapy versus Platinum-Doublet Chemotherapy in Early Stage NSCLC
This study looks at new ways to treat early-stage lung cancer. It compares standard chemotherapy with treatments that combine chemotherapy with new medicines called nivolumab and ipilimumab, to see if they work better at stopping the cancer from returning.
For: Early Stage Non-Small Cell Lung Cancer (NSCLC)France · Italy · Romania - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A multicentric phase 1/2 trial to evaluate the safety and efficacy of SOT102 as monotherapy and in combination with standard of care treatment in patients with gastric and pancreatic adenocarcinoma
This study is testing a new medicine called SOT102 for stomach and pancreatic cancer. Researchers want to find the safest dose of SOT102, both alone and with standard treatments, and see if it helps shrink tumours. It's an early-stage study, open to adults.
For: gastric adenocarcinoma or adenocarcinoma of the gastroesophageal junction (GEJ) and pancreatic adenocarcinomaSpain · Czechia · France